



FOR 9:00 AM (EST) RELEASE

Contact:

Aegera Therapeutics Inc.
514-288-5532, x225
Catherine So
Manager, Business Development
Email: catherine.so@aegera.com

AEGERA ESTABLISHES A CLINICAL ADVISORY BOARD

MONTREAL, October 14, 2004 - Aegera Therapeutics Inc. is pleased to announce the establishment of a Clinical Advisory Board to assist in the development of Aegera's cancer and cancer-related therapeutics.

"The creation of a Clinical Advisory Board is a significant milestone in a biotech's growth," stated Michael Atkin, President and CEO of Aegera. "We have solidified our access to world leading oncology expertise with a team of Board members who have a proven track record in understanding the intricacies of leading a drug successfully through clinical trials."

Aegera's Clinical Advisory Board includes:

Philip S. Schein, M.D., Chairman

Dr. Schein was the Founder, Chairman and Chief Executive Officer of U.S. Bioscience, Inc., a publicly held pharmaceutical company involved in the development and marketing of chemotherapeutic agents, from 1987 to 1998 where he took three products, Ethyol, Neutrexin and Hexalen, through development and regulatory approval in the US, Europe, Canada and other countries. His prior appointments included Scientific Director of the Vincent T. Lombardi Cancer Research Center at Georgetown University, Vice President for Worldwide Clinical Research and Development, SmithKline and French Labs and Senior Investigator and Head of the Clinical Pharmacology Section at the National Cancer Institute. He has served as President of the American Society of Clinical Oncology and has chaired the Food and Drug Administration Oncology Drugs Advisory Committee. Dr. Schein was appointed to the National Cancer Advisory Board by President Clinton. Presently, he serves as Visiting Professor in Cancer Pharmacology, University of Oxford, and as President of The Schein Group, which provides consultative services to the pharmaceutical/biotechnology industry. He has published over 350 papers in the field of cancer research and drug development and has 11 issued patents. Dr. Schein serves on the Board of Directors of Medicis and Targent.

Jacques Jolivet, M.D.

Dr. Jolivet is an active member of the American Association for Cancer Research and the American Society of Clinical Oncology. Currently, he holds a clinical position in the Hematology and Medical Oncology Service of the Hotel Dieu Hospital (St. Jerome, QC), and is an independent consultant to multiple drug discovery and pharmaceutical firms. Dr. Jolivet gained his medical degree in 1976 from the Universite de Montreal, and completed his medical oncology training with a 3-year fellowship in anti-cancer drug pharmacology at the US National Cancer Institute, in Bethesda, MD. Dr. Jolivet's basic research career spanned 15 years at the University of Montreal until 1998, when he became the Director of Clinical Oncology Development, at ShireBioChem until 2004. Dr. Jolivet has published more than 80 papers and has two issued patents. He has been the recipient of numerous grants and awards for his research in the field of oncology.

Kathleen I. Pritchard, M.D.

Dr. Pritchard is currently Chair of the Breast Cancer Site Group at the Toronto-Sunnybrook Regional Cancer Center and Sunnybrook and Women's College Health Sciences Center. She is head of the

Division of Clinical Trials and Epidemiology, Clinical Director of the Ontario Clinical Oncology Group, Co-Chair of the Breast Cancer Site Group of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG) and Professor of Medicine at the University of Toronto.

Apart from her ongoing clinical and administrative duties as a member of the Division of Medical Oncology/Haematology and Head of Clinical Trials & Epidemiology at the Toronto-Sunnybrook Regional Cancer Centre, Dr. Pritchard has maintained a productive program of research in the field of breast cancer. Dr. Pritchard is a frequent consultant for or member of independent data and safety monitoring committees for clinical trials world-wide.

Dr. Pritchard holds a major leadership role in a number of national and international multi-centre clinical trials, and is widely published in the major general medical and cancer journals.

About Aegera

Aegera Therapeutics Inc. is a private North American biotechnology company focused on exploiting apoptosis control to extend and enhance the lives of cancer patients: killing cancer cells by inducing apoptosis and rescuing nerve cells from apoptotic cell death caused by chemotherapy. Aegera's lead oncology product is a XIAP antisense therapeutic, AEG35156, developed in collaboration with Hybridon, Inc. Aegera's second oncology program is being developed to alleviate the disabling chemotherapy side-effect of peripheral neuropathy, and a lead product is scheduled to enter clinical trials by year end 2005. With the support of its strong intellectual property position, Aegera is committed to discovering and developing new apoptosis control drugs. For more information, please visit Aegera's website at www.aegera.com.